EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische Studie

A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia

Yunfei Chen iD, Yanmei Xu iD, Huiyuan Li, Ting Sun, Xuan Cao, Yuhua Wang, Feng Xue, Wei Liu, Xiaofan Liu, Huan Dong, Rongfeng Fu, Xinyue Dai und 9 weitere

New England Journal of Medicine · 20.06.2024 · 390 (23) · 2178-2190

DOI: 10.1056/nejmoa2400409 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 20.06.2024. Verfasst von Yunfei Chen und 20 weiteren Autor:innen. Beteiligte Einrichtung: From the National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, T…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Medical Sciences, Clinical Research Fund of National Center for Clinical Medical Research of Hematology Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalPurpura, Thrombocytopenic, IdiopathicAdultAgedAnimalsFemaleHumansMaleMiceMiddle AgedPlatelet CountMembrane GlycoproteinsADP-ribosyl Cyclase 1

Substanzen

Antibodies, MonoclonalCD38 protein, humanMembrane GlycoproteinsADP-ribosyl Cyclase 1

Autor:innen und Institutionen

  • From the National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, Chinese Acad…

ORCID-Profile: Yunfei Chen, Yanmei Xu

Förderung

  • National Natural Science Foundation of China
  • Chinese Academy of Medical Sciences
  • Clinical Research Fund of National Center for Clinical Medical Research of Hematology Diseases
  • CAMS Innovation Fund for Medical Sciences

Zitieren

APA

Chen, Y., Xu, Y., Li, H., Sun, T., Cao, X., Wang, Y., Xue, F., Liu, W., Liu, X., Dong, H., Fu, R., Dai, X., Wang, W., Ma, Y., Song, Z., Chi, Y., Ju, M., Gu, W., Pei, X., …, & Zhang, L. (2024). A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia. New England Journal of Medicine, 390(23), 2178-2190. https://doi.org/10.1056/nejmoa2400409

Vancouver

Chen Y, Xu Y, Li H, Sun T, Cao X, Wang Y, et al. A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia. New England Journal of Medicine. 2024;390(23):2178-2190. doi:10.1056/nejmoa2400409

BibTeX
@article{Chen2024,
  author = {Chen, Yunfei and Xu, Yanmei and Li, Huiyuan and Sun, Ting and Cao, Xuan and Wang, Yuhua and Xue, Feng and Liu, Wei and Liu, Xiaofan and Dong, Huan and Fu, Rongfeng and Dai, Xinyue and Wang, Wentian and Ma, Yueshen and Song, Zhen and Chi, Ying and Ju, Mankai and Gu, Wenjing and Pei, Xiaolei and Yang, Renchi and Zhang, Lei},
  title = {A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {23},
  pages = {2178--2190},
  doi = {10.1056/nejmoa2400409}
}
Kostenlos starten →